<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Vet Med Sci</journal-id><journal-id journal-id-type="iso-abbrev">J Vet Med Sci</journal-id><journal-id journal-id-type="pmc-domain-id">2350</journal-id><journal-id journal-id-type="pmc-domain">jvms</journal-id><journal-id journal-id-type="publisher-id">JVMS</journal-id><journal-title-group><journal-title>The Journal of Veterinary Medical Science</journal-title></journal-title-group><issn pub-type="ppub">0916-7250</issn><issn pub-type="epub">1347-7439</issn><publisher><publisher-name>Japanese Society of Veterinary Science</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10076201</article-id><article-id pub-id-type="pmcid-ver">PMC10076201.1</article-id><article-id pub-id-type="pmcaid">10076201</article-id><article-id pub-id-type="pmcaiid">10076201</article-id><article-id pub-id-type="pmid">36653162</article-id><article-id pub-id-type="doi">10.1292/jvms.22-0416</article-id><article-id pub-id-type="publisher-id">22-0416</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Internal Medicine</subject><subj-group><subject>Note</subject></subj-group></subj-group></article-categories><title-group><article-title>Distribution of enrofloxacin within the bronchoalveolar region of healthy pigs</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>IJIRI</surname><given-names initials="M">Moe</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>ISHIKAWA</surname><given-names initials="S">Shingo</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>HOBO</surname><given-names initials="S">Seiji</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="cor1" ref-type="corresp">
<sup>*</sup>
</xref></contrib><aff id="aff1"><label>1)</label>Joint Faculty of Veterinary Medicine, Kagoshima University, Kagoshima, Japan</aff><aff id="aff2"><label>2)</label>United Graduate School of Veterinary Sciences, Yamaguchi University, Yamaguchi, Japan</aff><aff id="aff3"><label>3)</label>Division of Veterinary Science Graduate School of Veterinary Science, Osaka Metropolitan University, Osaka, Japan</aff></contrib-group><author-notes><corresp id="cor1"><label>*</label>Correspondence to: Hobo S: <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="k2088185@kadai.jp">k2088185@kadai.jp</email>, Joint Faculty of Veterinary Medicine, Kagoshima University,
1-21-24 Korimoto, Kagoshima 890-0065, Japan</corresp></author-notes><pub-date pub-type="epub"><day>17</day><month>1</month><year>2023</year></pub-date><pub-date pub-type="ppub"><month>3</month><year>2023</year></pub-date><volume>85</volume><issue>3</issue><issue-id pub-id-type="pmc-issue-id">432895</issue-id><fpage>296</fpage><lpage>300</lpage><history><date date-type="received"><day>05</day><month>9</month><year>2022</year></date><date date-type="accepted"><day>26</day><month>12</month><year>2022</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>03</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>07</day><month>04</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-02-15 18:25:23.577"><day>15</day><month>02</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169;2023 The Japanese Society of Veterinary Science</copyright-statement><copyright-year>2023</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License. (CC-BY-NC-ND 4.0: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/"> https://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>)</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="jvms-85-296.pdf"/><abstract><p>This study aimed to elucidate the distribution of enrofloxacin (ERFX) within the bronchoalveolar region of pigs. Six clinically healthy pigs were allocated to intramuscular treatments with
either a single dose of 5 mg/kg or 7.5 mg/kg ERFX. Samples of plasma and bronchoalveolar lavage fluid (BALF) were obtained from each pig 0 (before administration), 3, 8, and 24 hr after ERFX
administration. The ERFX concentrations in pulmonary epithelial lining fluid (ELF) and BALF cells showed a similar pattern during the experimental period, whereby ERFX concentrations in both
ELF and BALF cells were higher than those in the plasma. These results suggest that intramuscularly injected ERFX is well-distributed in the bronchoalveolar region.</p></abstract><kwd-group><kwd>bronchoalveolar lavage fluid</kwd><kwd>distribution</kwd><kwd>enrofloxacin</kwd><kwd>pig</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>Respiratory diseases, generally caused by infections with viruses, bacteria, and mycoplasma, are common in modern swine production. Bronchopneumonia and subsequent pleuritis due to bacterial or
<italic toggle="yes">Mycoplasma</italic> spp. infections are frequent lesions of the lungs in pigs of all age groups [<xref rid="r24" ref-type="bibr">24</xref>]. Antimicrobials are generally used to treat
respiratory diseases caused by bacteria and <italic toggle="yes">Mycoplasma</italic> spp. Therefore, information on the distribution of antimicrobials within the bronchoalveolar region of pigs is important
and may aid in selecting appropriate antibacterial agents for the treatment of pneumonia, resulting in faster recovery from respiratory diseases.</p><p>Enrofloxacin (ERFX) is a quinolone-based agent with broad-spectrum antimicrobial activity against pathogens commonly associated with respiratory diseases in livestock [<xref rid="r4" ref-type="bibr">4</xref>, <xref rid="r21" ref-type="bibr">21</xref>]. Several different types of ERFX formulations are commercially available, including single-dose formulations containing higher
concentrations of ERFX to reduce labor and stress in livestock.</p><p>The pharmacokinetics and intrapulmonary distribution of ERFX must be characterized to determine whether it is an effective therapeutic agent for pneumonia. In particular, it is important to
determine whether the intrapulmonary ERFX concentration reaches the upper limit of the minimum inhibitory concentration (MIC) for the target pathogen [<xref rid="r16" ref-type="bibr">16</xref>].</p><p>The distribution of ERFX within the bronchoalveolar region has been reported in dogs following oral administration [<xref rid="r14" ref-type="bibr">14</xref>] and in calves after intramuscular
injection [<xref rid="r16" ref-type="bibr">16</xref>, <xref rid="r20" ref-type="bibr">20</xref>]. Although some pharmacokinetic (PK) studies of ERFX have been performed to elucidate its
biodistribution in pigs [<xref rid="r1" ref-type="bibr">1</xref>, <xref rid="r18" ref-type="bibr">18</xref>, <xref rid="r27" ref-type="bibr">27</xref>], no reports have been published concerning
the concentrations of ERFX within the bronchoalveolar region.</p><p>This study aimed to elucidate the concentration of ERFX in bronchoalveolar lavage fluid (BALF) after intramuscular ERFX administration to healthy pigs.</p><p>Six clinically healthy female pigs were used in this study. Pigs were determined to be healthy if they exhibited good appetite and vitality and did not exhibit coughing, fever, or abnormalities
in respiratory rate. The pigs used in the study were 12 weeks old and had a mean body weight of 44.7 &#177; 1.7 kg (mean &#177; SD, range: 42.0&#8211;47.2 kg). All protocols were approved by the Animal Care and
Use Committee of Kagoshima University (VM16062). Animals were cared for according to the Guide for the Care and Use of Laboratory Animals of the Joint Faculty of Veterinary Medicine, Kagoshima
University.</p><p>The pigs were randomized into two groups, with three pigs each, based on whether they were administered conventional or single-dose type ERFX formulation. Baytril<sup>&#174;</sup> 10% injectable
solution (5 mg/kg; Bayer [Elanco], Tokyo, Japan) was used as the conventional type, and Baytril<sup>&#174;</sup> 1ject (7.5 mg/kg; Bayer [Elanco]) as the single-dose type. Both formulations were
injected intramuscularly into each pig in a single dose.</p><p>Measurements of body temperature, heart rate, and respiratory rate, as well as peripheral venous blood samples, were obtained at 0 (before administration), 3, 8, and 24 hr after the injection.
Blood samples were collected in heparinized tubes (VP-H100K, Terumo, Tokyo, Japan) and Vacutainer tubes (VP-NA052K, Terumo) containing dipotassium ethylenediaminetetraacetic acid (EDTA-2AK).</p><p>Blood samples collected in tubes containing EDTA-2AK were used to determine white blood cell (WBC) and red blood cell (RBC) counts, hemoglobin (Hb) levels, and hematocrit (Ht). Measurements
were taken within 30 min of collection using an automated cell counter (Poch-100iV, Sysmex, Kobe, Japan). Plasma was separated from the blood collected in heparinized tubes by centrifugation
(4&#176;C, 2,000 g for 10 min) and stored at &#8722;80&#176;C until analysis. The urea concentrations within the plasma were measured using a colorimetric method with assay kits (Quantichrom Urea Assay Kit,
Bioassay Systems, Hayward, CA, USA). Bronchoalveolar lavage fluid (BALF) was collected using a flexible electronic endoscope (VQ TYPE 6112 B, Olympus, Tokyo, Japan) at 0 (before administration),
3, 8, and 24 hr after ERFX administration based on previously published reports [<xref rid="r5" ref-type="bibr">5</xref>, <xref rid="r17" ref-type="bibr">17</xref>]. Prior to the procedure, pigs
were administered 2 mg/kg of alfaxalone (Alfaxan, Meiji-Seika-Pharma, Tokyo, Japan) intramuscularly as a premedication. During BALF collection, anesthesia was maintained by inhalation of 2.5%
isoflurane through the nose using a mask (FO-20A, Acoma Medical Industry, Tokyo, Japan). BALF was sampled from one of five randomly selected lobes; accessory lobe, middle lobe, right caudal
lobe, left caudal lobe and left cranial lobe. Under general anesthesia, a flexible electronic endoscope was inserted into a subsegment of the lobe. Then, 30 mL of sterile 0.9% normal saline
solution was infused into each lobe through the forceps channel of the endoscope, followed by immediate aspiration. This procedure was performed twice for each lobe. Material from the second
aspiration was pooled with that of the first. Four samplings were performed per animal, all of which were sampled from different lobes. BALF specimens were immediately sent to a laboratory for
cell counting, and 1.5 mL of BALF from each of the four samples was centrifuged at 400 g for 5 min. The supernatant and cell pellets were separated and frozen at &#8722;80&#176;C until assays.</p><p>The concentrations of ERFX and ciprofloxacin (CPFX) were measured by high-performance liquid chromatography with tandem mass spectrometry (LC/MS/MS) based on the previously established
procedure reported by De Baere <italic toggle="yes">et al</italic>. [<xref rid="r8" ref-type="bibr">8</xref>]. Plasma samples (100 &#956;L) were diluted 10-fold with distilled water. Each BALF cell pellet sample
was mixed with 0.5 mL of 1 mol sodium hydroxide to lyse cells, and then each sample was mixed with 1.0 mL of 3% formic acid. Each sample (300 &#956;L, diluted plasma, supernatant of BALF, or lysed
BALF cell pellet) was mixed with 60 &#956;L of internal standard (Lomefloxacin, Sigma-Aldrich, Tokyo, Japan; 300 ng/mL in 1% formic acid/methanol [4:1]) and 60 &#956;L of methanol. The diluted sample (350
&#956;L) was loaded into a solid-phase extraction column (Oasis HLB; Waters, Tokyo, Japan). The residue was dissolved in 250 &#956;L of the mobile phase, and an aliquot (10 &#956;L) of the extract was injected
into the LC-MS/MS system (Prominence, Shimadzu, Kyoto, Japan; 4000 QTRAP, AB, Sciex, Tokyo, Japan). The detection limits for ERFX and CPFX were 0.001 &#956;g/mL.</p><p>The ERFX concentration was determined in the pulmonary epithelial lining fluid (ELF) and cells in BALF [<xref rid="r10" ref-type="bibr">10</xref>, <xref rid="r11" ref-type="bibr">11</xref>].
The concentration of ERFX in the ELF (<italic toggle="yes">ERFX<sub>ELF</sub></italic>) was calculated as follows:</p><p><italic toggle="yes">ERFX<sub>ELF</sub></italic>=<italic toggle="yes">ERFX<sub>BALF</sub></italic> X <italic toggle="yes">urea<sub>Plasma</sub> / urea<sub>BALF</sub></italic></p><p>where <italic toggle="yes">ERFX<sub>BALF</sub></italic> was the concentration of ERFX in BALF, <italic toggle="yes">urea<sub>Plasma</sub></italic> was the concentration of urea in plasma, and
<italic toggle="yes">urea<sub>BALF</sub></italic> was the concentration of urea in the BALF.</p><p>The concentration of ERFX in BALF cells (<italic toggle="yes">ERFX<sub>Cell</sub></italic>) was determined as follows:</p><p><italic toggle="yes">ERFX<sub>Cell</sub></italic>=<italic toggle="yes">ERFX<sub>PELLET</sub> / V<sub>cell</sub></italic></p><p>where <italic toggle="yes">ERFX<sub>PELLET</sub></italic> was the concentration of ERFX in the BALF cell pellet supernatant and <italic toggle="yes">V<sub>Cell</sub></italic> was the mean volume of BALF cells. A volume
of 1.28 &#956;L/10<sup>6</sup> BALF cells was used based on previous studies [<xref rid="r10" ref-type="bibr">10</xref>, <xref rid="r11" ref-type="bibr">11</xref>]. The area under the ERFX
concentration curve during the 0 to 24 hr timeframe (AUC<sub>0&#8211;24</sub>) was calculated using a method based on the previously established procedure reported by Wang <italic toggle="yes">et al</italic>.
[<xref rid="r26" ref-type="bibr">26</xref>].</p><p>Statistical analyses of the data were conducted using analysis of variance (one-way ANOVA) followed by the Tukey&#8211;Kramer multiple comparisons test to determine the differences in ERFX among the
three types of samples at the same sampling time. All statistical analyses were performed using IBM SPSS Statistics 25 software (IBM, Tokyo, Japan), and <italic toggle="yes">P</italic>&lt;0.05 was considered
statistically significant.</p><p>The body temperature, heart rate, and respiratory rate of the pigs barely fluctuated, and abnormal clinical findings were not detected via visual inspection during the experiment. The WBC, RBC,
Hb, and Ht values of the pigs barely fluctuated during the experiment.</p><p>The concentrations of CPFX, the primary metabolite of ERFX, were below the detection limits in all samples. Previous reports on the PK of ERFX also showed very low or below the detection limit
of CPFX [<xref rid="r19" ref-type="bibr">19</xref>, <xref rid="r27" ref-type="bibr">27</xref>], consistent with the results of this study. This suggests that ERFX is the main component
responsible for drug activity in pigs.</p><p>The ERFX concentrations in the plasma, ELF, and BALF cells are shown in <xref rid="fig_001" ref-type="fig">Fig. 1</xref><fig position="float" fig-type="figure" id="fig_001" orientation="portrait"><label>Fig. 1.</label><caption><p>Concentration of enrofloxacin determined within plasma, pulmonary epithelial lining fluid (ELF), and cells in bronchoalveolar lavage fluid (BALF cells) after intramuscular injection for
pigs. (<bold>A</bold>) Baytril 10% injectable solution (Dose: 5 mg/kg) (<bold>B</bold>) Baytril 1ject (Dose: 7.5 mg/kg). Data are shown as mean &#177; SD. Values with different letters indicate
significant differences between regions at the same sampling time (<italic toggle="yes">P</italic>&lt;0.05).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="jvms-85-296-g001.jpg"/></fig>. Both groups showed the highest concentrations in the plasma, ELF, and BALF cells at 8 hr. In pigs administered conventional ERFX, the mean ERFX concentration in ELF and BALF cells at 3
hr and 8 hr was significantly higher than that in plasma (<italic toggle="yes">P</italic>&lt;0.05). The dynamics of single-dose ERFX were similar; however, higher ERFX concentrations in the bronchoalveolar
region remained up to 24 hr after administration. In addition, the mean ERFX concentration in BALF cells at 3 hr was significantly higher than that in the plasma and ELF
(<italic toggle="yes">P</italic>&lt;0.05). Fluoroquinolones, including ERFX, accumulate in phagocytic cells, such as alveolar macrophages and achieve high intracellular concentrations [<xref rid="r23" ref-type="bibr">23</xref>]. In this study, the single-dose group was administered a higher dose than the conventional group, suggesting that the excess accumulated in alveolar cells. These results
demonstrate that intramuscularly administered ERFX in pigs was well distributed in the bronchoalveolar region.</p><p>In the present study, the plasma AUC was higher in proportion to the dose, which is consistent with a previous report [<xref rid="r3" ref-type="bibr">3</xref>]. The corresponding PK parameters
in the plasma, ELF, and BALF cells are presented in <xref rid="tbl_001" ref-type="table">Table 1</xref><table-wrap position="float" id="tbl_001" orientation="portrait"><label>Table 1.</label><caption><title>Pharmacokinetics (PK) parameters of enrofloxacine in plasma, pulmonary epithelial lining fluid and cells in bronchoalveolar lavage fluid (BALF cells) following single intramuscular
injection in pigs</title></caption><table frame="hsides" rules="groups"><col width="23.2558%" span="1"/><col width="12.2093%" span="1"/><col width="11.0465%" span="1"/><col width="15.1163%" span="1"/><col width="12.7907%" span="1"/><col width="11.0465%" span="1"/><col width="14.5349%" span="1"/><thead><tr><th rowspan="2" align="left" colspan="1"/><th colspan="3" align="center" rowspan="1">Conventional type (Baytril 10%, 5 mg/kg)<hr/></th><th colspan="3" align="center" rowspan="1">Single-dose type (Baytril 1ject, 7.5 mg/kg)<hr/></th></tr><tr><th align="center" rowspan="1" colspan="1">Cmax <break/>(&#956;g/mL)</th><th align="center" rowspan="1" colspan="1">Tmax <break/>(hr)</th><th align="center" rowspan="1" colspan="1">AUC<sub>0-24</sub>
<break/>(&#956;g&#183;hr/mL)</th><th align="center" rowspan="1" colspan="1">Cmax <break/>(&#956;g/mL)</th><th align="center" rowspan="1" colspan="1">Tmax <break/>(hr)</th><th align="center" rowspan="1" colspan="1">AUC<sub>0-24</sub>
<break/>(&#956;g&#183;hr/mL)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Plasma</td><td align="center" rowspan="1" colspan="1">0.92 &#177; 0.03 <sup>a</sup></td><td align="center" rowspan="1" colspan="1">6.33 &#177; 2.89</td><td align="center" rowspan="1" colspan="1">18.45 &#177; 0.62 <sup>a</sup></td><td align="center" rowspan="1" colspan="1">1.27 &#177; 0.18 <sup>a</sup></td><td align="center" rowspan="1" colspan="1">8.00 &#177; 0.00</td><td align="center" rowspan="1" colspan="1">24.30 &#177; 3.58 <sup>a</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Pulmonary epithelial lining fluid</td><td align="center" rowspan="1" colspan="1">11.44 &#177; 1.56 <sup>b</sup></td><td align="center" rowspan="1" colspan="1">8.00 &#177; 0.00</td><td align="center" rowspan="1" colspan="1">200.92 &#177; 12.52 <sup>b</sup></td><td align="center" rowspan="1" colspan="1">13.46 &#177; 2.85 <sup>b</sup></td><td align="center" rowspan="1" colspan="1">8.00 &#177; 0.00</td><td align="center" rowspan="1" colspan="1">238.36 &#177; 42.80 <sup>b</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">BALF cells</td><td align="center" rowspan="1" colspan="1">13.06 &#177; 5.88 <sup>b</sup></td><td align="center" rowspan="1" colspan="1">8.00 &#177; 0.00</td><td align="center" rowspan="1" colspan="1">227.44 &#177; 105.29 <sup>b</sup></td><td align="center" rowspan="1" colspan="1">17.22 &#177; 1.32 <sup>b</sup></td><td align="center" rowspan="1" colspan="1">8.00 &#177; 0.00</td><td align="center" rowspan="1" colspan="1">309.45 &#177; 17.54 <sup>c</sup></td></tr></tbody></table><table-wrap-foot><p>Data are shown as the mean &#177; SD. Cmax: peak concentration; Tmax: time to Cmax; AUC<sub>0-24</sub>: area under the curve of enrofloxacin from 0 to 24 hr after intramuscular injection in
pigs. Values with the different letter indicate the significant differences among each region in PK parameters (<italic toggle="yes">P</italic>&lt;0.05).</p></table-wrap-foot></table-wrap>. The mean value of peak ERFX concentration (Cmax) and AUC<sub>0&#8211;24</sub> in ELF and BALF cells were significantly higher than those in plasma (<italic toggle="yes">P</italic>&lt;0.05).
Additionally, in the single-dose group, the AUC in BALF cells was significantly higher than that in ELF.</p><p>To provide effective treatment of bacterial pneumonia, prediction of the antimicrobial effect of the agent is required, which is based on both effective PK and pharmacodynamic (PD) analyses.
Such combined PK/PD approaches have been widely used in clinical practice [<xref rid="r6" ref-type="bibr">6</xref>]. Generally, the blood concentration of antimicrobial agents and the MIC
against causative bacteria are used as indicators. In other words, it is considered important that antimicrobial components are distributed at the site of bacterial infection and exceed the MIC
for that particular bacterium.</p><p>In previous surveys in Europe, the MIC<sub>90</sub> values of ERFX against porcine strains of <italic toggle="yes">Pasteurella multocida</italic>,<italic toggle="yes"> Actinobacillus pleuropneumoniae</italic>,<italic toggle="yes">
Streptococcus suis</italic>, and <italic toggle="yes">Mycoplasma hyopneumoniae</italic> were 0.03 &#181;g/mL, 0.06 &#181;g/mL, 0.5 &#181;g/mL, and 0.5 &#181;g/mL, respectively [<xref rid="r9" ref-type="bibr">9</xref>, <xref rid="r15" ref-type="bibr">15</xref>]. According to a susceptibility study conducted in Japan using bovine or porcine clinical isolates, ERFX MIC<sub>90</sub> against <italic toggle="yes">P.
multocida</italic>, <italic toggle="yes">Mannheimia haemolytica</italic>, and <italic toggle="yes">A. pleuropneumoniae</italic> have been reported to be 0.12 &#181;g/mL, 0.5 &#181;g/mL, and 0.5 &#181;g/mL, respectively [<xref rid="r13" ref-type="bibr">13</xref>]. In the present study, ERFX concentrations in ELF and BALF cells remained well above 1.00 &#181;g/mL from 3 to 24 hr after administering either formulation.
Thus, ERFX concentrations in the bronchoalveolar region were higher than the MIC<sub>90</sub> for these bacteria.</p><p>Fluoroquinolones, such as ERFX exhibit concentration-dependent killing [<xref rid="r22" ref-type="bibr">22</xref>]. Therefore, the AUC<sub>0&#8211;24</sub> to MIC ratio (AUC/MIC) was used as an index
of the microbiocidal activity [<xref rid="r22" ref-type="bibr">22</xref>, <xref rid="r25" ref-type="bibr">25</xref>]. Although data are based on human clinical trials and laboratory animal
infection models, for fluoroquinolones, AUC/MIC greater than 100&#8211;125 is generally associated with treatment efficacy [<xref rid="r2" ref-type="bibr">2</xref>, <xref rid="r22" ref-type="bibr">22</xref>, <xref rid="r25" ref-type="bibr">25</xref>, <xref rid="r28" ref-type="bibr">28</xref>]. Assuming MIC of 0.5 &#181;g/mL based on previous report on <italic toggle="yes">A. pleuropneumoniae</italic>
[<xref rid="r13" ref-type="bibr">13</xref>], a typical swine respiratory disease-causing bacterium, the AUC/MIC in plasma, ELF, and alveolar cells were 37, 402, and 455, respectively, for the
conventional type, and 49, 477 and 619, respectively, for the single-dose type. These data suggest that sufficient amounts of ERFX are likely to be distributed in the bronchoalveolar region at
doses of 5 mg/kg and 7.5 mg/kg. Previous field studies have reported good therapeutic effects of ERFX in the treatment of respiratory diseases [<xref rid="r12" ref-type="bibr">12</xref>], and
these results support our findings.</p><p>In this study, both formulations were expected to reach the bronchoalveolar region with sufficient concentrations of ERFX; however, the single-dose formulation maintained high ERFX
concentrations in the bronchoalveolar region even 24 hr after administration. This would be beneficial for treating bacterial pneumonia in the two points below. First, efficacy can be achieved
with a single dose, leading to labor savings. This is a significant advantage in large-scale swine rearing. However, because the present study only confirmed the pharmacokinetics up to 24 hr
after administration, it may be necessary to confirm the concentration after that. The other is to minimize concerns about antimicrobial resistance. The concept of mutant prevention
concentration (MPC) is important in this issue, and Damte <italic toggle="yes">et al.</italic> [<xref rid="r7" ref-type="bibr">7</xref>] reported an MPC<sub>90</sub> of 8 &#181;g/mL for <italic toggle="yes">A.
pleuropneumoniae</italic> isolated from pigs. In this study, the mean ERFX concentrations (mean&#177; SD) in the ELF and BALF cells at 8 hr after administration were 11.44 &#177; 1.56 &#181;g/mL and 13.06 &#177;
5.88 &#181;g/mL for the conventional form and 13.46 &#177; 2.85 &#181;g/mL and 17.22 &#177; 1.32 &#181;g/mL for the single-dose form (<xref rid="fig_001" ref-type="fig">Fig. 1</xref>). Furthermore, in the single-dose
group, the ERFX concentration in ELF and alveolar cells remained above the MPC value until 24 hr after administration (8.3 &#177; 1.6 &#181;g/mL and 10.7 &#177; 2.7 &#181;g/mL, respectively). As a countermeasure
against antimicrobial resistance, it is important to distribute drug components efficiently to the site of infection. The single-dose formulation allows a relatively large amount to be
administered at once and is distributed at high concentrations at the site of infection, suggesting that it may be one way to prevent the emergence of resistant strains in respiratory
disease-causing bacteria.</p><p>In the present study, we demonstrated the distribution of ERFX in the bronchoalveolar region after intramuscular injection in healthy pigs. In both conventional and single-dose formulations,
ERFX was shown to be efficiently distributed into the bronchoalveolar region and maintain sufficient concentrations up to 24 hr after administration. Additional pharmacokinetic and
pharmacodynamic studies, including microbiological research on other pathogens, are required to evaluate the efficacy of ERFX treatment for porcine respiratory diseases further.</p><sec sec-type="COI-statement" id="s1"><title>CONFLICT OF INTEREST</title><p>The authors have no conflict of interest to declare. This study was supported by grants from the Bayer Yakuhin Ltd (Elanco Japan K.K.).</p></sec></body><back><ack><p>We thank Ms. Kono for her help in analyzing the pharmacokinetic parameters.</p></ack><ref-list><title>REFERENCES</title><ref id="r1"><label>1</label><mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Ahmad</surname><given-names>SU</given-names></name><name name-style="western"><surname>Sun</surname><given-names>J</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>F</given-names></name><name name-style="western"><surname>Li</surname><given-names>B</given-names></name><name name-style="western"><surname>Arbab</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name></person-group>. <year>2021</year>. <article-title>Comparative study on pharmacokinetics of four long-acting injectable formulations of enrofloxacin in pigs</article-title>.
<source><italic toggle="yes">Front Vet Sci</italic></source><volume>7</volume>: <fpage>604628</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fvets.2020.604628</pub-id><pub-id pub-id-type="pmid">33575278</pub-id><pub-id pub-id-type="pmcid">PMC7870480</pub-id></mixed-citation></ref><ref id="r2"><label>2</label><mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>AliAbadi</surname><given-names>FS</given-names></name><name name-style="western"><surname>Lees</surname><given-names>P</given-names></name></person-group>. <year>2000</year>. <article-title>Antibiotic treatment for animals: effect on bacterial population and dosage regimen optimisation</article-title>. <source><italic toggle="yes">Int J
Antimicrob Agents</italic></source><volume>14</volume>: <fpage>307</fpage>&#8211;<lpage>313</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0924-8579(00)00142-4</pub-id><pub-id pub-id-type="pmid">10794952</pub-id></mixed-citation></ref><ref id="r3"><label>3</label><mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Bimazubute</surname><given-names>M</given-names></name><name name-style="western"><surname>Cambier</surname><given-names>C</given-names></name><name name-style="western"><surname>Baert</surname><given-names>K</given-names></name><name name-style="western"><surname>Vanbelle</surname><given-names>S</given-names></name><name name-style="western"><surname>Chiap</surname><given-names>P</given-names></name><name name-style="western"><surname>Albert</surname><given-names>A</given-names></name><name name-style="western"><surname>Delporte</surname><given-names>JP</given-names></name><name name-style="western"><surname>Gustin</surname><given-names>P</given-names></name></person-group>. <year>2010</year>. <article-title>Penetration of enrofloxacin into the nasal secretions and relationship between nasal secretions and plasma enrofloxacin concentrations
after intramuscular administration in healthy pigs</article-title>. <source><italic toggle="yes">J Vet Pharmacol Ther</italic></source><volume>33</volume>: <fpage>183</fpage>&#8211;<lpage>188</lpage>. doi:
<pub-id pub-id-type="doi">10.1111/j.1365-2885.2009.01123.x</pub-id><pub-id pub-id-type="pmid">20444043</pub-id></mixed-citation></ref><ref id="r4"><label>4</label><mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Blondeau</surname><given-names>JM</given-names></name><name name-style="western"><surname>Fitch</surname><given-names>SD</given-names></name></person-group>. <year>2019</year>. <article-title>Mutant prevention and minimum inhibitory concentration drug values for enrofloxacin, ceftiofur, florfenicol, tilmicosin and tulathromycin
tested against swine pathogens <italic toggle="yes">Actinobacillus pleuropneumoniae, Pasteurella multocida</italic> and <italic toggle="yes">Streptococcus suis</italic></article-title>. <source><italic toggle="yes">PLoS
One</italic></source><volume>14</volume>: <fpage>e0210154</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0210154</pub-id><pub-id pub-id-type="pmid">30629633</pub-id><pub-id pub-id-type="pmcid">PMC6328246</pub-id></mixed-citation></ref><ref id="r5"><label>5</label><mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Boothe</surname><given-names>HW</given-names></name><name name-style="western"><surname>Jones</surname><given-names>SA</given-names></name><name name-style="western"><surname>Wilkie</surname><given-names>WS</given-names></name><name name-style="western"><surname>Boeckh</surname><given-names>A</given-names></name><name name-style="western"><surname>Stenstrom</surname><given-names>KK</given-names></name><name name-style="western"><surname>Boothe</surname><given-names>DM</given-names></name></person-group>. <year>2005</year>. <article-title>Evaluation of the concentration of marbofloxacin in alveolar macrophages and pulmonary epithelial lining fluid after administration in
dogs</article-title>. <source><italic toggle="yes">Am J Vet Res</italic></source><volume>66</volume>: <fpage>1770</fpage>&#8211;<lpage>1774</lpage>. doi: <pub-id pub-id-type="doi">10.2460/ajvr.2005.66.1770</pub-id><pub-id pub-id-type="pmid">16273909</pub-id></mixed-citation></ref><ref id="r6"><label>6</label><mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Craig</surname><given-names>WA</given-names></name></person-group>. <year>1998</year>. <article-title>Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men</article-title>. <source><italic toggle="yes">Clin Infect
Dis</italic></source><volume>26</volume>: <fpage>1</fpage>&#8211;<lpage>10, quiz 11&#8211;12</lpage>. doi: <pub-id pub-id-type="doi">10.1086/516284</pub-id><pub-id pub-id-type="pmid">9455502</pub-id></mixed-citation></ref><ref id="r7"><label>7</label><mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Damte</surname><given-names>D</given-names></name><name name-style="western"><surname>Lee</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Yohannes</surname><given-names>SB</given-names></name><name name-style="western"><surname>Hossain</surname><given-names>MA</given-names></name><name name-style="western"><surname>Suh</surname><given-names>JW</given-names></name><name name-style="western"><surname>Park</surname><given-names>SC</given-names></name></person-group>. <year>2013</year>. <article-title>Comparative activities of selected fluoroquinolones against dynamic populations of <italic toggle="yes">Actinobacillus pleuropneumoniae</italic> in an
in vitro model of time-kill continuous culture experiment</article-title>. <source><italic toggle="yes">Int J Antimicrob Agents</italic></source><volume>42</volume>:
<fpage>544</fpage>&#8211;<lpage>552</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ijantimicag.2013.08.011</pub-id><pub-id pub-id-type="pmid">24139884</pub-id></mixed-citation></ref><ref id="r8"><label>8</label><mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>De Baere</surname><given-names>S</given-names></name><name name-style="western"><surname>Goossens</surname><given-names>J</given-names></name><name name-style="western"><surname>Osselaere</surname><given-names>A</given-names></name><name name-style="western"><surname>Devreese</surname><given-names>M</given-names></name><name name-style="western"><surname>Vandenbroucke</surname><given-names>V</given-names></name><name name-style="western"><surname>De Backer</surname><given-names>P</given-names></name><name name-style="western"><surname>Croubels</surname><given-names>S</given-names></name></person-group>. <year>2011</year>. <article-title>Quantitative determination of T-2 toxin, HT-2 toxin, deoxynivalenol and deepoxy-deoxynivalenol in animal body fluids using LC-MS/MS
detection</article-title>. <source><italic toggle="yes">J Chromatogr B Analyt Technol Biomed Life Sci</italic></source><volume>879</volume>: <fpage>2403</fpage>&#8211;<lpage>2415</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jchromb.2011.06.036</pub-id><pub-id pub-id-type="pmid">21767999</pub-id></mixed-citation></ref><ref id="r9"><label>9</label><mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>de Jong</surname><given-names>A</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>V</given-names></name><name name-style="western"><surname>Simjee</surname><given-names>S</given-names></name><name name-style="western"><surname>Moyaert</surname><given-names>H</given-names></name><name name-style="western"><surname>El Garch</surname><given-names>F</given-names></name><name name-style="western"><surname>Maher</surname><given-names>K</given-names></name><name name-style="western"><surname>Morrissey</surname><given-names>I</given-names></name><name name-style="western"><surname>Butty</surname><given-names>P</given-names></name><name name-style="western"><surname>Klein</surname><given-names>U</given-names></name><name name-style="western"><surname>Marion</surname><given-names>H</given-names></name><name name-style="western"><surname>Rigaut</surname><given-names>D</given-names></name><name name-style="western"><surname>Vall&#233;</surname><given-names>M</given-names></name></person-group>. <year>2014</year>. <article-title>Antimicrobial susceptibility monitoring of respiratory tract pathogens isolated from diseased cattle and pigs across Europe: the VetPath
study</article-title>. <source><italic toggle="yes">Vet Microbiol</italic></source><volume>172</volume>: <fpage>202</fpage>&#8211;<lpage>215</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.vetmic.2014.04.008</pub-id><pub-id pub-id-type="pmid">24837878</pub-id></mixed-citation></ref><ref id="r10"><label>10</label><mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Gigu&#232;re</surname><given-names>S</given-names></name><name name-style="western"><surname>Huang</surname><given-names>R</given-names></name><name name-style="western"><surname>Malinski</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Dorr</surname><given-names>PM</given-names></name><name name-style="western"><surname>Tessman</surname><given-names>RK</given-names></name><name name-style="western"><surname>Somerville</surname><given-names>BA</given-names></name></person-group>. <year>2011</year>. <article-title>Disposition of gamithromycin in plasma, pulmonary epithelial lining fluid, bronchoalveolar cells, and lung tissue in
cattle</article-title>. <source><italic toggle="yes">Am J Vet Res</italic></source><volume>72</volume>: <fpage>326</fpage>&#8211;<lpage>330</lpage>. doi: <pub-id pub-id-type="doi">10.2460/ajvr.72.3.326</pub-id><pub-id pub-id-type="pmid">21355734</pub-id></mixed-citation></ref><ref id="r11"><label>11</label><mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Gotfried</surname><given-names>MH</given-names></name><name name-style="western"><surname>Danziger</surname><given-names>LH</given-names></name><name name-style="western"><surname>Rodvold</surname><given-names>KA</given-names></name></person-group>. <year>2001</year>. <article-title>Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects</article-title>.
<source><italic toggle="yes">Chest</italic></source><volume>119</volume>: <fpage>1114</fpage>&#8211;<lpage>1122</lpage>. doi: <pub-id pub-id-type="doi">10.1378/chest.119.4.1114</pub-id><pub-id pub-id-type="pmid">11296178</pub-id></mixed-citation></ref><ref id="r12"><label>12</label><mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Grandemange</surname><given-names>E</given-names></name><name name-style="western"><surname>Perrin</surname><given-names>PA</given-names></name><name name-style="western"><surname>Cvejic</surname><given-names>D</given-names></name><name name-style="western"><surname>Haas</surname><given-names>M</given-names></name><name name-style="western"><surname>Rowan</surname><given-names>T</given-names></name><name name-style="western"><surname>Hellmann</surname><given-names>K</given-names></name></person-group>. <year>2017</year>. <article-title>Randomised controlled field study to evaluate the efficacy and clinical safety of a single 8 mg/kg injectable dose of marbofloxacin
compared with one or two doses of 7.5 mg/kg injectable enrofloxacin for the treatment of <italic toggle="yes">Actinobacillus pleuropneumoniae</italic> infections in growing-fattening pigs in
Europe</article-title>. <source><italic toggle="yes">Porcine Health Manag</italic></source><volume>3</volume>: <fpage>10</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s40813-017-0057-2</pub-id><pub-id pub-id-type="pmid">28496988</pub-id><pub-id pub-id-type="pmcid">PMC5424389</pub-id></mixed-citation></ref><ref id="r13"><label>13</label><mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Harada</surname><given-names>K</given-names></name><name name-style="western"><surname>Usui</surname><given-names>M</given-names></name><name name-style="western"><surname>Asai</surname><given-names>T</given-names></name></person-group>. <year>2014</year>. <article-title>Application of enrofloxacin and orbifloxacin disks approved in Japan for susceptibility testing of representative veterinary respiratory
pathogens</article-title>. <source><italic toggle="yes">J Vet Med Sci</italic></source><volume>76</volume>: <fpage>1427</fpage>&#8211;<lpage>1430</lpage>. doi: <pub-id pub-id-type="doi">10.1292/jvms.14-0266</pub-id><pub-id pub-id-type="pmid">25008965</pub-id><pub-id pub-id-type="pmcid">PMC4221182</pub-id></mixed-citation></ref><ref id="r14"><label>14</label><mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Hawkins</surname><given-names>EC</given-names></name><name name-style="western"><surname>Boothe</surname><given-names>DM</given-names></name><name name-style="western"><surname>Guinn</surname><given-names>A</given-names></name><name name-style="western"><surname>Aucoin</surname><given-names>DP</given-names></name><name name-style="western"><surname>Ngyuen</surname><given-names>J</given-names></name></person-group>. <year>1998</year>. <article-title>Concentration of enrofloxacin and its active metabolite in alveolar macrophages and pulmonary epithelial lining fluid of
dogs</article-title>. <source><italic toggle="yes">J Vet Pharmacol Ther</italic></source><volume>21</volume>: <fpage>18</fpage>&#8211;<lpage>23</lpage>. doi: <pub-id pub-id-type="doi">10.1046/j.1365-2885.1998.00103.x</pub-id><pub-id pub-id-type="pmid">9507453</pub-id></mixed-citation></ref><ref id="r15"><label>15</label><mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Klein</surname><given-names>U</given-names></name><name name-style="western"><surname>de Jong</surname><given-names>A</given-names></name><name name-style="western"><surname>Moyaert</surname><given-names>H</given-names></name><name name-style="western"><surname>El Garch</surname><given-names>F</given-names></name><name name-style="western"><surname>Leon</surname><given-names>R</given-names></name><name name-style="western"><surname>Richard-Mazet</surname><given-names>A</given-names></name><name name-style="western"><surname>Rose</surname><given-names>M</given-names></name><name name-style="western"><surname>Maes</surname><given-names>D</given-names></name><name name-style="western"><surname>Pridmore</surname><given-names>A</given-names></name><name name-style="western"><surname>Thomson</surname><given-names>JR</given-names></name><name name-style="western"><surname>Ayling</surname><given-names>RD</given-names></name></person-group>. <year>2017</year>. <article-title>Antimicrobial susceptibility monitoring of <italic toggle="yes">Mycoplasma hyopneumoniae</italic> and <italic toggle="yes">Mycoplasma bovis</italic> isolated in
Europe</article-title>. <source><italic toggle="yes">Vet Microbiol</italic></source><volume>204</volume>: <fpage>188</fpage>&#8211;<lpage>193</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.vetmic.2017.04.012</pub-id><pub-id pub-id-type="pmid">28532800</pub-id></mixed-citation></ref><ref id="r16"><label>16</label><mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Kuramae</surname><given-names>T</given-names></name><name name-style="western"><surname>Otomaru</surname><given-names>K</given-names></name><name name-style="western"><surname>Hirata</surname><given-names>M</given-names></name><name name-style="western"><surname>Ishikawa</surname><given-names>S</given-names></name><name name-style="western"><surname>Noguchi</surname><given-names>M</given-names></name><name name-style="western"><surname>Ikedo</surname><given-names>T</given-names></name><name name-style="western"><surname>Horinouchi</surname><given-names>C</given-names></name><name name-style="western"><surname>Hayashi</surname><given-names>J</given-names></name><name name-style="western"><surname>Tsumagari</surname><given-names>K</given-names></name><name name-style="western"><surname>Hobo</surname><given-names>S</given-names></name></person-group>. <year>2020</year>. <article-title>Pharmacokinetics in plasma and alveolar regions of healthy calves subcutaneously administered a single dose of
enrofloxacin</article-title>. <source><italic toggle="yes">J Vet Med Sci</italic></source><volume>82</volume>: <fpage>1197</fpage>&#8211;<lpage>1203</lpage>. doi: <pub-id pub-id-type="doi">10.1292/jvms.20-0110</pub-id><pub-id pub-id-type="pmid">32565494</pub-id><pub-id pub-id-type="pmcid">PMC7468075</pub-id></mixed-citation></ref><ref id="r17"><label>17</label><mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>McKellar</surname><given-names>Q</given-names></name><name name-style="western"><surname>Gibson</surname><given-names>I</given-names></name><name name-style="western"><surname>Monteiro</surname><given-names>A</given-names></name><name name-style="western"><surname>Bregante</surname><given-names>M</given-names></name></person-group>. <year>1999</year>. <article-title>Pharmacokinetics of enrofloxacin and danofloxacin in plasma, inflammatory exudate, and bronchial secretions of calves following
subcutaneous administration</article-title>. <source><italic toggle="yes">Antimicrob Agents Chemother</italic></source><volume>43</volume>: <fpage>1988</fpage>&#8211;<lpage>1992</lpage>. doi: <pub-id pub-id-type="doi">10.1128/AAC.43.8.1988</pub-id><pub-id pub-id-type="pmid">10428924</pub-id><pub-id pub-id-type="pmcid">PMC89402</pub-id></mixed-citation></ref><ref id="r18"><label>18</label><mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Messenger</surname><given-names>KM</given-names></name><name name-style="western"><surname>Papich</surname><given-names>MG</given-names></name><name name-style="western"><surname>Blikslager</surname><given-names>AT</given-names></name></person-group>. <year>2012</year>. <article-title>Distribution of enrofloxacin and its active metabolite, using an in vivo ultrafiltration sampling technique after the injection of
enrofloxacin to pigs</article-title>. <source><italic toggle="yes">J Vet Pharmacol Ther</italic></source><volume>35</volume>: <fpage>452</fpage>&#8211;<lpage>459</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1365-2885.2011.01338.x</pub-id><pub-id pub-id-type="pmid">21913941</pub-id></mixed-citation></ref><ref id="r19"><label>19</label><mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Nielsen</surname><given-names>P</given-names></name><name name-style="western"><surname>Gyrd-Hansen</surname><given-names>N</given-names></name></person-group>. <year>1997</year>. <article-title>Bioavailability of enrofloxacin after oral administration to fed and fasted pigs</article-title>. <source><italic toggle="yes">Pharmacol
Toxicol</italic></source><volume>80</volume>: <fpage>246</fpage>&#8211;<lpage>250</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1600-0773.1997.tb01967.x</pub-id><pub-id pub-id-type="pmid">9181604</pub-id></mixed-citation></ref><ref id="r20"><label>20</label><mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Otomaru</surname><given-names>K</given-names></name><name name-style="western"><surname>Hirata</surname><given-names>M</given-names></name><name name-style="western"><surname>Ikedo</surname><given-names>T</given-names></name><name name-style="western"><surname>Horinouchi</surname><given-names>C</given-names></name><name name-style="western"><surname>Noguchi</surname><given-names>M</given-names></name><name name-style="western"><surname>Ishikawa</surname><given-names>S</given-names></name><name name-style="western"><surname>Nagata</surname><given-names>S</given-names></name><name name-style="western"><surname>Hobo</surname><given-names>S</given-names></name></person-group>. <year>2016</year>. <article-title>Intrapulmonary concentration of enrofloxacin in healthy calves</article-title>. <source><italic toggle="yes">J Vet Med
Sci</italic></source><volume>78</volume>: <fpage>681</fpage>&#8211;<lpage>683</lpage>. doi: <pub-id pub-id-type="doi">10.1292/jvms.15-0495</pub-id><pub-id pub-id-type="pmid">26668174</pub-id><pub-id pub-id-type="pmcid">PMC4873861</pub-id></mixed-citation></ref><ref id="r21"><label>21</label><mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Prescott</surname><given-names>JF</given-names></name><name name-style="western"><surname>Yielding</surname><given-names>KM</given-names></name></person-group>. <year>1990</year>. <article-title>In vitro susceptibility of selected veterinary bacterial pathogens to ciprofloxacin, enrofloxacin and norfloxacin</article-title>.
<source><italic toggle="yes">Can J Vet Res</italic></source><volume>54</volume>: <fpage>195</fpage>&#8211;<lpage>197</lpage>. <pub-id pub-id-type="pmid">2306672</pub-id><pub-id pub-id-type="pmcid">PMC1255628</pub-id></mixed-citation></ref><ref id="r22"><label>22</label><mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Schentag</surname><given-names>JJ</given-names></name></person-group>. <year>2000</year>. <article-title>Clinical pharmacology of the fluoroquinolones: studies in human dynamic/kinetic models</article-title>. <source><italic toggle="yes">Clin Infect
Dis</italic></source><volume>31</volume><issue>Suppl 2</issue>: <fpage>S40</fpage>&#8211;<lpage>S44</lpage>. doi: <pub-id pub-id-type="doi">10.1086/314059</pub-id><pub-id pub-id-type="pmid">10984327</pub-id></mixed-citation></ref><ref id="r23"><label>23</label><mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Schoevers</surname><given-names>EJ</given-names></name><name name-style="western"><surname>van Leengoed</surname><given-names>LA</given-names></name><name name-style="western"><surname>Verheijden</surname><given-names>JH</given-names></name><name name-style="western"><surname>Niewold</surname><given-names>TA</given-names></name></person-group>. <year>1999</year>. <article-title>Effects of enrofloxacin on porcine phagocytic function</article-title>. <source><italic toggle="yes">Antimicrob Agents
Chemother</italic></source><volume>43</volume>: <fpage>2138</fpage>&#8211;<lpage>2143</lpage>. doi: <pub-id pub-id-type="doi">10.1128/AAC.43.9.2138</pub-id><pub-id pub-id-type="pmid">10471554</pub-id><pub-id pub-id-type="pmcid">PMC89436</pub-id></mixed-citation></ref><ref id="r24"><label>24</label><mixed-citation publication-type="book"><person-group><name name-style="western"><surname>Straw</surname><given-names>BE</given-names></name><name name-style="western"><surname>D&#8217;Allaire</surname><given-names>S</given-names></name><name name-style="western"><surname>Mengeling</surname><given-names>W</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>D</given-names></name></person-group>., editors. <year>1999</year>. Diseases of swine, 8th ed., Iowa State University Press, Ames.</mixed-citation></ref><ref id="r25"><label>25</label><mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Thomas</surname><given-names>JK</given-names></name><name name-style="western"><surname>Forrest</surname><given-names>A</given-names></name><name name-style="western"><surname>Bhavnani</surname><given-names>SM</given-names></name><name name-style="western"><surname>Hyatt</surname><given-names>JM</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>A</given-names></name><name name-style="western"><surname>Ballow</surname><given-names>CH</given-names></name><name name-style="western"><surname>Schentag</surname><given-names>JJ</given-names></name></person-group>. <year>1998</year>. <article-title>Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during
therapy</article-title>. <source><italic toggle="yes">Antimicrob Agents Chemother</italic></source><volume>42</volume>: <fpage>521</fpage>&#8211;<lpage>527</lpage>. doi: <pub-id pub-id-type="doi">10.1128/AAC.42.3.521</pub-id><pub-id pub-id-type="pmid">9517926</pub-id><pub-id pub-id-type="pmcid">PMC105492</pub-id></mixed-citation></ref><ref id="r26"><label>26</label><mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S</given-names></name><name name-style="western"><surname>Quinney</surname><given-names>SK</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>J</given-names></name><name name-style="western"><surname>Li</surname><given-names>L</given-names></name></person-group>. <year>2010</year>. <article-title>Non-compartment model to compartment model pharmacokinetics transformation meta-analysis-a multivariate nonlinear mixed
model</article-title>. <source><italic toggle="yes">BMC Syst Biol</italic></source><volume>4</volume><issue>Suppl 1</issue>: <fpage>S8</fpage>. doi: <pub-id pub-id-type="doi">10.1186/1752-0509-4-S1-S8</pub-id><pub-id pub-id-type="pmid">20522258</pub-id><pub-id pub-id-type="pmcid">PMC2880414</pub-id></mixed-citation></ref><ref id="r27"><label>27</label><mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Wiuff</surname><given-names>C</given-names></name><name name-style="western"><surname>Lykkesfeldt</surname><given-names>J</given-names></name><name name-style="western"><surname>Aarestrup</surname><given-names>FM</given-names></name><name name-style="western"><surname>Svendsen</surname><given-names>O</given-names></name></person-group>. <year>2002</year>. <article-title>Distribution of enrofloxacin in intestinal tissue and contents of healthy pigs after oral and intramuscular
administrations</article-title>. <source><italic toggle="yes">J Vet Pharmacol Ther</italic></source><volume>25</volume>: <fpage>335</fpage>&#8211;<lpage>342</lpage>. doi: <pub-id pub-id-type="doi">10.1046/j.1365-2885.2002.00430.x</pub-id><pub-id pub-id-type="pmid">12423223</pub-id></mixed-citation></ref><ref id="r28"><label>28</label><mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Wright</surname><given-names>DH</given-names></name><name name-style="western"><surname>Brown</surname><given-names>GH</given-names></name><name name-style="western"><surname>Peterson</surname><given-names>ML</given-names></name><name name-style="western"><surname>Rotschafer</surname><given-names>JC</given-names></name></person-group>. <year>2000</year>. <article-title>Application of fluoroquinolone pharmacodynamics</article-title>. <source><italic toggle="yes">J Antimicrob
Chemother</italic></source><volume>46</volume>: <fpage>669</fpage>&#8211;<lpage>683</lpage>. doi: <pub-id pub-id-type="doi">10.1093/jac/46.5.669</pub-id><pub-id pub-id-type="pmid">11062185</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>